Catalent Adds Capacity at Kansas City Clinical Supplies Facility
The second phase of a $5.5-million expansion adds controlled-substance and controlled-temperature storage to Catalent clinical trials facility.
Catalent Pharma Solutions announced on May 17, 2018 the completion of the second phase of a $5.5-million expansion program at its Kansas City, MO facility, which increased the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
The expansion included a Drug Enforcement Administration Schedule I and II controlled substance vault; 3600-sq.-ft. of additional storage; controlled-temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations; a sampling room; and an emergency generator.
The 450,000-sq.-ft. facility provides development and analytical support through to packaging and distribution, the company reported in a press statement. Previously, the company announced expansions at clinical supply facilities in Philadelphia and Singapore.
Source: Catalent Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
